Ep160: Abe Ceesay on Precision Neuroscience

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.

Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.

Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.

Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.